# ADAR1 Partners

> ADAR1 Partners is a VC fund backing Medical, Biotechnology and Pharmaceutical. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Feb 2025
- Lead investor: 67%
- Last updated: Aug 2026

ADAR1 Partners is a VC fund focused on Medical and Biotechnology. ADAR1 Partners operates as an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 67% |
| Biotechnology | 2 | 67% |
| Pharmaceutical | 2 | 67% |
| Internet | 1 | 33% |
| Health Care | 1 | 33% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 2 | 67% |
| Series D | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| Canada | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Grace Therapeutics (formerly Acasti Pharma) | Grace Therapeutics is an emerging biopharmaceutical company dedicated to the research, development, and commercialization of innovative proprietary active pharmaceutical ingredients (API) for managing cardiometabolic disorders, from prevention to treatment, through a novel superior approach to lipid regulation. | $10.5M | Post-IPO Equity | Feb 10, 2025 |  |
| Kiora Pharmaceuticals | EyeGate Pharmaceuticals is a clinical-stage specialty pharmaceutical company that develops medicines to treat eye diseases using its non-invasive, iontophoretic drug-delivery system. It is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGateÂII. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both pre-clinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic diseases in the mid and posterior segments of the eye is less than adequate. They believe the EyeGate II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease. | $15M | Post-IPO Equity | Jan 31, 2024 |  |
| Outdoorsy | Outdoorsy is a marketplace platform that connects RV owners with other campers.Lots of folks own RVs. Lots of folks want to rent RVs. Outdoorsy is how they meet.Outdoorsy is the first peer-to-peer marketplace to disrupt the $32B recreational vehicle industry. We connect passionate RV owners with qualified renters and make it easy and safe forthem to transact.They're disrupting the RV market by removing all the friction and complexity from the current user experience. They provide choice and access for people who love to travel in RVs, as well as the opportunity for RV owners to make a tangible income from renting their vehicle. | $90M | Series D | Jun 24, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Nantahala Capital Management](https://shizune.co/investors/profile/nantahala-capital-management) — VC Fund, 2 deals together
- [Stonepine Capital Management](https://shizune.co/investors/profile/stonepine-capital-management) — VC Fund, 2 deals together
- [Altos Ventures](https://shizune.co/investors/profile/altos-ventures) — VC Fund, 1 deal together
- [Convivialite Ventures](https://shizune.co/investors/profile/convivialite-ventures) — VC Fund, 1 deal together
- [Greenspring Associates](https://shizune.co/investors/profile/greenspring-associates) — VC Fund, 1 deal together
- [iAngels](https://shizune.co/investors/profile/iangels) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does ADAR1 Partners invest in?

ADAR1 Partners invests primarily in Medical, Biotechnology and Pharmaceutical startups, most often at Post-IPO Equity and Series D stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did ADAR1 Partners last invest?

The most recent investment recorded for ADAR1 Partners closed in Feb 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co